Covidien and Mallinckrodt to Present at Bank of America Merrill Lynch Conference

Updated

Covidien and Mallinckrodt to Present at Bank of America Merrill Lynch Conference

MANSFIELD, Mass.--(BUSINESS WIRE)-- Covidien (NYS: COV) , a leading global provider of healthcare products, will present at the Bank of America Merrill Lynch 2013 Health Care Conference in Las Vegas, NV, on Wednesday, May 15, 2013.

Bryan Hanson, Group President, Surgical Solutions, will represent the Company in a session scheduled at 1:40 p.m. ET.


Mark Trudeau, President, Pharmaceuticals, will discuss Mallinckrodt, the pharmaceuticals business of Covidien, in a session scheduled to begin at 2:20 p.m. ET.

A live audio webcast of the presentations can be accessed at Covidien's Investor Relations website: http://investor.covidien.com.

ABOUT COVIDIEN
Covidien is a leading global healthcare products company that creates innovative medical solutions for better patient outcomes and delivers value through clinical leadership and excellence. Covidien manufactures, distributes and services a diverse range of industry-leading product lines in three segments: Medical Devices, Pharmaceuticals and Medical Supplies. With 2012 revenue of $11.9 billion, Covidien has 43,000 employees worldwide in 70 countries, and its products are sold in over 140 countries. Please visit www.covidien.com to learn more about our business.



Covidien
Jacqueline Strayer, 508-261-8305
Senior Vice President
Corporate Communications
jacqueline.strayer@covidien.com
or
Coleman Lannum, CFA, 508-452-4343
Vice President
Investor Relations
cole.lannum@covidien.com
or
Bruce Farmer, 508-452-4372
Vice President
Public Relations
bruce.farmer@covidien.com
or
Todd Carpenter, 508-452-4363
Senior Director
Investor Relations
todd.carpenter@covidien.com

KEYWORDS: United States North America Massachusetts Nevada

INDUSTRY KEYWORDS:

The article Covidien and Mallinckrodt to Present at Bank of America Merrill Lynch Conference originally appeared on Fool.com.

Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Advertisement